What we have achieved
Assessment of vaccine management effectiveness
An external mission reviewed the situation and found an overall effectiveness of 83% for all levels of the supply chain, which demonstrates significant improvement compared with the previous assessment conducted in 2014. Except for vaccine arrival (E1 ), maintenance (E5), and general vaccine management (E9), which were a bit below expectation, other criteria were satisfactory. In general, the vaccine supply chain management system was satisfactory and met most of the assessed criteria. An improvement plan has been developed to improve the situation.
Improving adverse events following immunization reporting for COVID-19 vaccines
The Center for Communicable Diseases Control has been supported to enhance adverse events following immunization reporting for COVID-19 vaccines.
Revised national guidelines for measles and rubella vaccination post elimination under development
What is next
- Increasing cold chain capacity (procurement).
- Establishing a rotavirus surveillance system.
- Developing national guidelines for adult vaccination against emerging and re-emerging infections.
